TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO

TAIPEI, Taiwan, Aug. 30, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. ("TWi") (stock ticker: 4180.TT) announced that its President and CEO Ms. Tina Guilder will resign from her current roles.  Chairman Dr. Chih-Ming Chen will become interim President and CEO, leading TWi in its aim to maintain its growth momentum.

Dr. Chen is the founder of TWi and in his role as Chairman has historically been the chief architect of TWi's strategy.  Taking the CEO role personally, he will focus on operating strategies, making precise product selections, motivating top management and all employees, and integrating the business groups' resources to strengthen the core competencies of TWi.

TWi believes, that the sales strategies for its commercialized generic products will benefit from Dr. Chen's experience, including successfully establishing generic pharmaceutical businesses in the U.S. market and his deep relationships in the industry.  Dr. Chen will also lead the Company in its continued execution and strengthening of its research and development, business strategies and further promotion of its business expansion in the United States and international generics markets.  TWi believes that, under Dr. Chen's leadership, it will maintain its growth momentum.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high-entry-barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and oral delivery systems.  Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States.  For more information of TWi Pharmaceuticals, please visit